Ireland - English - HPRA (Health Products Regulatory Authority)

pharmaswiss ceska republika s.r.o. - megestrol acetate - tablet - 160 milligram(s) - progestogens; megestrol

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

bausch & lomb uk ltd - megestrol acetate - oral tablet - 160mg

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - megestrol acetate 160mg;   - tablet - 160 mg - active: megestrol acetate 160mg   excipient: colloidal silicon dioxide lactose monohydrate magnesium stearate microcrystalline cellulose povidone sodium starch glycolate

United States - English - NLM (National Library of Medicine)

par pharmaceutical, inc. - megestrol acetate (unii: tj2m0fr8es) (megestrol - unii:ea6ld1m70m) - megestrol acetate oral suspension (125 mg/ml) is indicated for the treatment of anorexia, cachexia, or an unexplained significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (aids). limitations of use therapy with megestrol acetate for weight loss should only be instituted after treatable causes of weight loss are sought and addressed. these treatable causes include possible malignancies, systemic infections, gastrointestinal disorders affecting absorption, endocrine disease, renal disease or psychiatric diseases. megestrol acetate is not intended for prophylactic use to avoid weight loss. - history of hypersensitivity to megestrol acetate or any component of the formulation. - pregnancy [see warnings and precautions (5.2), use in specific populations (8.1, 8.3)] . risk summary based on animal data, megestrol acetate may cause fetal harm when administered to a pregnant woman and is contraindicated during pregnancy [see contraindications (4)] . there are no available human da

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - megestrol acetate (unii: tj2m0fr8es) (megestrol - unii:ea6ld1m70m) - megestrol acetate oral suspension (125 mg/ml) is indicated for the treatment of anorexia, cachexia, or an unexplained significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (aids). limitations of use therapy with megestrol acetate for weight loss should only be instituted after treatable causes of weight loss are sought and addressed. these treatable causes include possible malignancies, systemic infections, gastrointestinal disorders affecting absorption, endocrine disease, renal disease or psychiatric diseases. megestrol acetate is not intended for prophylactic use to avoid weight loss. - history of hypersensitivity to megestrol acetate or any component of the formulation. - pregnancy [see warnings and precautions (5.2), use in specific populations (8.1, 8.3)] . risk summary based on animal data, megestrol acetate may cause fetal harm when administered to a pregnant woman and is contraindicated during pregnancy [see contraindications (4)] . there are no available human da

Ireland - English - HPRA (Health Products Regulatory Authority)

ltt pharma limited - megestrol acetate - tablet - 160 milligram(s) - progestogens; megestrol

Ireland - English - HPRA (Health Products Regulatory Authority)

pco manufacturing ltd. - megestrol acetate - tablet - 160 milligram(s) - progestogens; megestrol

Ireland - English - HPRA (Health Products Regulatory Authority)

imed healthcare ltd. - megestrol acetate - tablet - progestogens; megestrol

Canada - English - Health Canada

pharmel inc - azithromycin (azithromycin monohydrate hemiethanolate) - powder for suspension - 100mg - azithromycin (azithromycin monohydrate hemiethanolate) 100mg - other macrolides

Canada - English - Health Canada

pharmel inc - azithromycin (azithromycin monohydrate hemiethanolate) - powder for suspension - 200mg - azithromycin (azithromycin monohydrate hemiethanolate) 200mg - other macrolides